Asset Details
Do you wish to reserve the book?
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
Do you wish to request the book?
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
2010
Overview
Background:
Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC).
Methods:
Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome.
Results:
CAIX tissue overexpression correlated with shorter overall survival (OS) (
P
=0.05) and disease-specific survival (DSS) of patients (
P
=0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (
P
<0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (
P
<0.001) and DSS (
P
<0.001), mostly in early stage I+II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (
P
=0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (
P
<0.001) in patients with NSCLC.
Conclusion:
High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I+II carcinomas.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Cancer Research UK
Subject
/ Adult
/ Aged
/ Antigens, Neoplasm - metabolism
/ Biological and medical sciences
/ Biomarkers, Tumor - metabolism
/ Biomedical and Life Sciences
/ Carbonic Anhydrases - metabolism
/ Carcinoma, Non-Small-Cell Lung
/ Carcinoma, Non-Small-Cell Lung - blood
/ Carcinoma, Non-Small-Cell Lung - diagnosis
/ Carcinoma, Non-Small-Cell Lung - metabolism
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Female
/ Humans
/ Male
/ Oncology
/ Tumors
